Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Buy
55
ALDX Quote, Financials, Valuation and Earnings
Last price:
$5.05
Seasonality move
:
6.3%
Day range:
$4.90 - $5.75
52-week range:
$1.14 - $7.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
6.16x
Volume:
1.5M
Avg. volume:
1.3M
1-year change:
13.52%
Market cap:
$303.5M
Revenue:
--
EPS (TTM):
-$0.72
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
|
-- | -$0.16 | -- | -44.74% | $9.67 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$277.2M | $0.15 | 12.96% | -83.59% | $29.79 |
|
ADMA
ADMA Biologics, Inc.
|
$130.5M | $0.16 | 18.97% | -56.04% | $25.67 |
|
EXEL
Exelixis, Inc.
|
$590.2M | $0.67 | 7.5% | 59.24% | $45.28 |
|
KRYS
Krystal Biotech, Inc.
|
$93.4M | $1.12 | 16.27% | 5.57% | $229.00 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$58.7M | -- | 11.45% | -- | $11.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
|
$5.05 | $9.67 | $303.5M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$27.83 | $29.79 | $4.7B | 17.91x | $0.00 | 0% | 4.48x |
|
ADMA
ADMA Biologics, Inc.
|
$19.50 | $25.67 | $4.6B | 22.89x | $0.00 | 0% | 9.81x |
|
EXEL
Exelixis, Inc.
|
$46.61 | $45.28 | $12.5B | 19.62x | $0.00 | 0% | 5.83x |
|
KRYS
Krystal Biotech, Inc.
|
$253.36 | $229.00 | $7.3B | 38.00x | $0.00 | 0% | 20.26x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$6.84 | $11.75 | $404.2M | -- | $0.00 | 0% | 1.89x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
|
23.99% | 1.936 | 4.95% | 2.64x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.330 | 1.52% | 2.70x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
EXEL
Exelixis, Inc.
|
7.55% | 0.460 | 1.59% | 3.47x |
|
KRYS
Krystal Biotech, Inc.
|
0.83% | 0.141 | 0.19% | 9.43x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | 0.085 | 3.7% | 2.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
|
-$63.7K | -$8M | -53.75% | -66.61% | -- | -$7M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
EXEL
Exelixis, Inc.
|
$579.2M | $256.4M | 28.73% | 31.26% | 42.89% | $288.8M |
|
KRYS
Krystal Biotech, Inc.
|
$92.1M | $41.4M | 19.74% | 19.91% | 42.31% | $38M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
Aldeyra Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ALDX or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of 25.76%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About ALDX or ACAD?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 74.49%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $29.79 which suggests that it could grow by 6.16%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.4 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is ALDX or ACAD More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.831, which suggesting that the stock is 16.879% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.982%.
-
Which is a Better Dividend Stock ALDX or ACAD?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or ACAD?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 17.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 4.48x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M ACADACADIA Pharmaceuticals, Inc.4.48x 17.91x $278.6M $71.8M
-
Which has Higher Returns ALDX or ADMA?
ADMA Biologics, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of 27.14%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About ALDX or ADMA?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 74.49%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 29.11%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.4 0 0 ADMAADMA Biologics, Inc.3 0 0 -
Is ALDX or ADMA More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.831, which suggesting that the stock is 16.879% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.
-
Which is a Better Dividend Stock ALDX or ADMA?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or ADMA?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 22.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 9.81x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M ADMAADMA Biologics, Inc.9.81x 22.89x $134.2M $36.4M
-
Which has Higher Returns ALDX or EXEL?
Exelixis, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of 32.38%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat Exelixis, Inc.'s return on equity of 31.26%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M EXELExelixis, Inc.96.89% $0.70 $2.3B -
What do Analysts Say About ALDX or EXEL?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 74.49%. On the other hand Exelixis, Inc. has an analysts' consensus of $45.28 which suggests that it could fall by -2.86%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Exelixis, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Exelixis, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.4 0 0 EXELExelixis, Inc.9 9 0 -
Is ALDX or EXEL More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.831, which suggesting that the stock is 16.879% less volatile than S&P 500. In comparison Exelixis, Inc. has a beta of 0.400, suggesting its less volatile than the S&P 500 by 59.967%.
-
Which is a Better Dividend Stock ALDX or EXEL?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. Exelixis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or EXEL?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than Exelixis, Inc. quarterly revenues of $597.8M. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is lower than Exelixis, Inc.'s net income of $193.6M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Exelixis, Inc.'s PE ratio is 19.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 5.83x for Exelixis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M EXELExelixis, Inc.5.83x 19.62x $597.8M $193.6M
-
Which has Higher Returns ALDX or KRYS?
Krystal Biotech, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of 81.15%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat Krystal Biotech, Inc.'s return on equity of 19.91%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B -
What do Analysts Say About ALDX or KRYS?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 74.49%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $229.00 which suggests that it could fall by -9.62%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.4 0 0 KRYSKrystal Biotech, Inc.10 1 0 -
Is ALDX or KRYS More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.831, which suggesting that the stock is 16.879% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.528%.
-
Which is a Better Dividend Stock ALDX or KRYS?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or KRYS?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than Krystal Biotech, Inc. quarterly revenues of $97.8M. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Krystal Biotech, Inc.'s PE ratio is 38.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 20.26x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M KRYSKrystal Biotech, Inc.20.26x 38.00x $97.8M $79.4M
-
Which has Higher Returns ALDX or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of -40.15%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About ALDX or VNDA?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 74.49%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 71.78%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Vanda Pharmaceuticals, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Vanda Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.4 0 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is ALDX or VNDA More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.831, which suggesting that the stock is 16.879% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.
-
Which is a Better Dividend Stock ALDX or VNDA?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or VNDA?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 1.89x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M VNDAVanda Pharmaceuticals, Inc.1.89x -- $56.3M -$22.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 3.24% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 1.39% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.1% over the past day.
